(NVET) Provides Update on Upcoming Investor Symposium at Irish Biomanufacturing Facility

DUBLIN, Ireland, May 27, 2016  — Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, is pleased to provide an update on its Investor Symposium, which will be held on Friday June 3, 2016 at BioNua, its veterinary biologics manufacturing facility in Tullamore, Ireland.

The Symposium’s presentations and Q&A session will be held from 9:30AM – 10:30AM IST. In addition to providing an overview of the BioNua facility and its capabilities, the company will present a corporate and clinical update. Key topics will include progress on ranevetmab (NV-01) and NV-02, Nexvet’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapies being developed as monthly subcutaneous injectables for the control of pain associated with osteoarthritis in dogs and cats, respectively.

“Dedicated in-house manufacturing is an important element of Nexvet’s strategy for furthering our leadership position in the emerging field of veterinary biopharmaceuticals. The BioNua facility is an asset which we anticipate will provide added control, cost advantages and overall enhanced efficiency in manufacturing, both for our advanced pain product candidates for dogs and cats as well as our emerging pipeline in immuno-oncology, allergy and inflammation. These advantages are particularly important as we plan further pivotal studies and prepare our commercial infrastructure,” commented Dr. Mark Heffernan, Chief Executive Officer of Nexvet.

The audio and presentations from this event will be made available for 30 days on the Investor Relations section of the Nexvet website at www.ir.nexvet.com.

To register to attend Nexvet’s Investor Symposium in Tullamore, please RSVP to IR@nexvet.com with your name, company and phone number.

About Nexvet (www.nexvet.com)

Nexvet is a veterinary biologics developer focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and is growing its biomanufacturing capabilities in Ireland.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements consist of all statements other than statements of historical fact, including statements regarding our future results of operations and financial position, results of any current or future pivotal safety and efficacy study, future expenditures relating to our lead product candidates, time for completion of any of our studies or facilities updates, ability to develop our pipeline of product candidates, business strategy, prospective products, ability to successfully manufacture our own product candidates, ability to meet conditions for the receipt of government grants, ability to qualify for conditional licensure or obtain product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.  The words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “position,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.  These forward-looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors.

Factors that could cause actual results to differ materially from our expectations expressed in this report include those summarized under Risk Factors in our reports on Forms 10-Q and 10-K and the other documents we file from time to time with the Securities and Exchange Commission. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent management’s beliefs and assumptions only as of the date of this press release. Except as required by law, we do not intend, and undertake no obligation, to revise or update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Further information:

Investors                                                                       
Candice Knoll                                                                 
Blueprint Life Science Group                                         
+1 415-375-3340 Ext. 4                                                                      
cknoll@bplifescience.com                                            

Media
Jessica Burns
Berry & Company Public Relations
+1 212-253-8881
jburns@berrypr.com